Medical device maker Stryker disclosed last month that federal authorities—for the third time in a decade—are investigating whether the company broke a federal anti-bribery law.
The Department of Justice and Securities and Exchange Commission inquiry is a stark reminder that even as compliance teams struggle to keep up with new regulations, including state privacy and pay-transparency laws, the decades-old Foreign Corrupt Practices Act still looms as a colossal risk for multinational companies.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
